|1.||Li, Wei: 5 articles (07/2015 - 01/2010)|
|2.||Slominski, Andrzej T: 5 articles (07/2015 - 01/2010)|
|3.||Tuckey, Robert C: 5 articles (07/2015 - 01/2010)|
|4.||Janjetovic, Zorica: 4 articles (05/2013 - 01/2010)|
|5.||Kim, Tae-Kang: 3 articles (07/2015 - 12/2010)|
|6.||Chen, Jianjun: 3 articles (05/2013 - 12/2010)|
|7.||Miller, Duane: 3 articles (09/2012 - 01/2010)|
|8.||But, W M: 2 articles (12/2015 - 12/2012)|
|9.||Thompson, Ian M: 2 articles (11/2015 - 10/2011)|
|10.||Wang, Jin: 2 articles (07/2015 - 09/2012)|
|1.||Prostatic Neoplasms (Prostate Cancer)
11/01/2008 - "A microsatellite polymorphism (TTTTA)n in the promoter region of the CYP11A1 gene has been reported to be associated with an increased risk of metastatic and high-grade prostate cancer. "
11/01/2008 - "The presence of the CYP11A1 (TTTTA)6 allele increases the risk of biochemical relapse in organ confined and low-grade prostate cancer."
11/01/2008 - "In the present study of 110 prostate cancer patients and 96 population controls, we examined the association between the CYP11A1 (TTTTA)n polymorphism and prostate cancer risk, aggressiveness, and incidence of biochemical relapse after prostatectomy. "
05/20/2004 - "In our study which included 278 prostate cancer patients, 213 benign prostatic hyperplasia (BPH) patients and 299 male controls, we explored the association between the CYP11A1 polymorphism and prostate cancer on the hypothesis that the presence of the (tttta)4 allele may increase the risk of the development or progression of prostate cancer. "
05/20/2004 - "Our results suggest that the CYP11A1 polymorphism may have a significant influence on the development of advanced and/or high grade prostate cancer and the absence of the CYP11A1 (tttta)4 allele, i.e., the homozygosity for the (tttta)6 or longer allele, could be a useful marker for the prediction of disease progression of prostate cancer."
|2.||Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
05/20/2004 - "Recent studies suggested that the absence of the shortest (tttta)4 allele of the CYP11A1 polymorphism was associated with a risk of polycystic ovary syndrome and with a hyperandrogenic state in polycystic ovary syndrome patients. "
07/01/2014 - "Polymorphisms of pentanucleotide repeats (tttta)n in the promoter of CYP11A1 and their relationships to polycystic ovary syndrome (PCOS) risk: a meta-analysis."
08/01/2012 - "Association between polymorphisms of the CYP11A1 gene and polycystic ovary syndrome in Chinese women."
03/01/2010 - "[Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome]."
01/01/2010 - "[(TTTTA), polymorphism in the promoter of the CYP11A1 gene in the pathogenesis of polycystic ovary syndrome]."
|3.||Endometrial Neoplasms (Endometrial Cancer)
04/01/2012 - "Variations in CYP11A1 may modify the effect of ET use on risk of postmenopausal endometrial cancer; however, larger studies are needed to explore these findings further."
05/01/2010 - "We genotyped four CYP11A1 tagging single nucleotide polymorphisms (SNPs) and two StAR SNPs in endometrial cancer case-control studies nested within the Nurses' Health Study (553 cases and 1339 controls) and the Women's Health Study (137 cases and 411 controls). "
05/01/2010 - "Genetic variants in CYP11A1 may influence endometrial cancer risk or may be markers for causal variants elsewhere. "
05/01/2010 - "Genetic variation in CYP11A1 and StAR in relation to endometrial cancer risk."
02/25/2013 - "This down-regulation of STAR, CYP11A1 and PGR in endometrial cancer may lead to decreased progesterone biosynthesis and actions although the effects on progesterone levels should be further studied."
|4.||Breast Neoplasms (Breast Cancer)
01/01/2012 - "In this study, the associations between single nucleotide polymorphisms (SNPs) in CYP11A1 and breast cancer susceptibility were examined. "
06/15/2007 - "Here, we conduct a systematic investigation of the role of genetic variation of the CYP11A1 gene in breast cancer risk in a study of 1193 breast cancer cases and 1310 matched controls from the Shanghai Breast Cancer Study. "
01/01/2012 - "Our results suggest that polymorphisms of CYP11A1 are related to breast cancer susceptibility in Han Chinese women of South China."
01/01/2012 - "Risk-association of CYP11A1 polymorphisms and breast cancer among Han Chinese women in Southern China."
06/01/2009 - "Notably, osteoblasts and breast cancer cells express an approximately 32-kDa truncated isoform of Cyp11a1 that is nonmitochondrial and localized in both the cytoplasm and the nucleus. "
12/01/1991 - "Normal genes for the cholesterol side chain cleavage enzyme, P450scc, in congenital lipoid adrenal hyperplasia."
04/01/1986 - "Deficient SCC activity causes congenital lipoid adrenal hyperplasia (also known as 20,22 desmolase deficiency), a potentially lethal defect in the synthesis of all steroid hormones. "
06/15/1977 - "Cholesterol side-chain cleavage enzyme activity and cytochrome P-450 content in adrenal mitochondria of a patient with congenital lipoid adrenal hyperplasia (Prader disease)."
04/01/1986 - "Study of cholesterol side-chain cleavage (20,22 desmolase) deficiency causing congenital lipoid adrenal hyperplasia using bovine-sequence P450scc oligodeoxyribonucleotide probes."
03/01/2011 - "Partial defect in the cholesterol side-chain cleavage enzyme P450scc (CYP11A1) resembling nonclassic congenital lipoid adrenal hyperplasia."
|1.||Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)
|2.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|4.||steroidogenic acute regulatory protein
|5.||Steroid 11-beta-Hydroxylase (11 beta-Hydroxylase)
|2.||Prostatectomy (Retropubic Prostatectomy)